Table 2.
Numbers of participants with metabolic syndrome (related components) and eGFR-defined CKD
| Traits | No. (%) of All Participants | No. (%) of Men | No. (%) of Women | No. (%) with Missing Data |
|---|---|---|---|---|
| Hypertension treatment | 5979 (63) | 2697 (64) | 3282 (62) | 0 |
| Diabetes treatment | 1040 (11) | 597 (14) | 443 (8) | 0 |
| Abdominal obesity | 3397 (36) | 1170 (28) | 2227 (42) | 63 |
| Hyperglycemia | 3491(37) | 1907 (46) | 1584 (30) | 2 |
| Hypertriglyceridemia | 2240 (24) | 1115 (27) | 1125 (21) | 2 |
| Low HDL | 2703 (29) | 1392 (33) | 1311 (25) | 1 |
| Dyslipidemia | 3665 (39) | 1857(44) | 1808 (34) | 1 |
| Hypertension | 7446 (79) | 3393(81) | 4053 (77) | 167 |
| Metabolic syndrome | 3180 (34) | 1529(37) | 1651 (31) | 0 |
| CKD | 1896 (20) | 822 (20) | 1074 (20) | 0 |
In total, 9442 twins (4183 men and 5259 women) are included in the twin study. eGFR calculated by the cystatin C–based equations from the CKD Epidemiology Collaboration group; CKD cases defined by eGFR<60 ml/min per 1.73 m2. Percentages of numbers of participants who meet the criteria in each group are presented in the brackets. Metabolic syndrome is defined by the National Cholesterol Education Program-Adult Treatment Panel III guideline, cases are identified if more than three of the following criteria are met: abdominal obesity (waist circumference >40 inches for men, >35 inches for women), hyperglycemia (fasting glucose ≥100 mg/dl or any antidiabetic treatment), hypertriglyceridemia (triglycerides ≥150 mg/dl or any triglyceride-lowering treatment), low HDL (HDL <40 mg/dl for men, <50 mg/dl for women, or any lipid-lowering treatments), and hypertension (systolic BP >130 mm Hg or diastolic BP >85 mm Hg, or any antihypertensive treatment).